Frequently Asked Questions

Here are some useful questions and answers we’ve collated along the way. We recommend checking here before contacting the ASCEND team, in case your query has already been answered.

Please check back as this section will be updated regularly.

Yes – Up to £100 per completed face-to-face visit (V1, V5, V6).

Receipts or proof of cost must be submitted.

It is still considered one visit (V1) – only one £100 travel reimbursement is allowed.

Yes, £100 inconvenience fee per completed face-to-face visit (V1, V5, V6).

Yes – but please bear in mind this may be reviewed if the number rises above levels seen at other sites.

No. Double the amount of IMP/placebo needed to meet the recruitment target has been delivered to avoid any issues with supply

Each IMP kit is supplied with a kit/randomization number. Once the participant has been randomized, a blinded email will be sent to the study team (members designated to receive notification emails) and pharmacy team members, confirming the kit number to dispense.

No – this is accessible via the study eCRF.

No – as they only receive notification emails. Email addresses will be uploaded into the randomization system.

Yes. Nurses are considered designees under the protocol.

No. Direct in-room supervision is not required. The investigator must provide supervisory support and be available if queries arise.

Yes. Please record the time taken out for processing and time returned to fridge (if applicable), to cover cancellations or delays.

Up to 7 days cumulative at <30°C while in its carton.

Outside 2–8°C. A temperature excursion reporting form must be completed.

Sites may use their own destruction log (template to be shared with Sponsor). Logs must be signed by delegated personnel. A Destruction Certificate is acceptable, but logs with signatures are also valid. Sponsor approval is required before destruction.

No – once randomization has taken place, the kit number specified must be dispensed for the linked participant. In the event this kit is not used, it should be placed in quarantine with a notification sent to the Sponsor.

It is possible – please contact the ASCEND team with any specific scenarios

Yes! Please contact the ASCEND team ASAP with details as it takes time to set them up.

Liver function tests only, as per protocol v2.2 onwards.

Yes. From protocol v2.2 onwards, this can be done for any reason, as long as the visit is completed within seven days.

Yes – seven days if possible.

Yes they can – either at a local site or GP.

Please provide a phlebotomy form to participants and assist with arranging a phlebotomy appointment.

Participants will need to arrange phlebotomy appointments within the protocol defined window

No – the cost for this is included in the site funding provided

No – they are trial-specific blood tests and the costs are included in the site funding provided

All blood samples will be processed by the local hospital laboratory.

No. Local procedures should be followed – a lab manual will not be provided.

No. Temperature excursion reporting refers only to IMP storage/handling.

For the full 35-week study duration, until the last visit.

Scroll to Top